Rocket Pharmaceuticals, Inc.

RCKT

N/A

NASDAQGene Therapy🇺🇸North America299 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

May 15, 2026

21w

Drug Pipeline

Drug Name	Phase	Indication	Designations
RP-L201	Phase 2	Leukocyte Adhesion Defect - Type I	-
RP-L102	Phase 2	Fanconi Anemia Complementation Group A	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

May 2026~RP-L102

Primary completion for RP-L102 trial (NCT04248439) in Fanconi Anemia Complementation Group A

Regulatory Approvals

RCKT News